Prusogliptin
AssetAlso DBPR-108
Dipeptidyl peptidase-4 (DPP-4) inhibitor improving glycemic control
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- DPP4
- 1
- Indication
- 388
- Trials
- 1
- Developer
Indications
1Type 2 diabetes
Phase 3, Active not recruiting, NCT07026968, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials388
- Evidence for its targets2
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.